Please see Important Safety Information on pages 7S to 9S. Please see Brief Summary
of the full Prescribing Information, including Boxed WARNING, on pages 11S–16S.
A Treatment Option for Relapsed
or Refractory Mantle Cell Lymphoma
A SUPPLEMENT TO VOL. 32 SUPPL. 5
This supplement is sponsored by Celgene Corporation.
Featured Expert
ANDRE GOY, MD, MS
Chairman and Director
Lymphoma Division Chief
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey
Chief Science Officer and Director of Research and Innovation
Regional Cancer Care Associates
Hackensack, New Jersey
Professor of Medicine
Georgetown University
Washington, District of Columbia
ACADEMIC AND MEDICAL
APPOINTMENTS
Dr. Goy is a Professor of Medicine at
Georgetown University and serves as Chief
Science Officer and Director of Innovation
for Regional Cancer Care Associates,
a large regional oncology network. Dr.
Goy is a member of several professional
associations including the American
Society of Hematology and the American
Society of Clinical Oncology. He has
published more than 100 articles and is a
reviewer for a number of journals including
Journal of Clinical Oncology, Blood, Cancer,
and Clinical Cancer Research. Dr. Goy
is also the Editor-in-Chief of Oncology &
Biotech News and serves on the board of
COTA, an informatics health care company
he founded with his colleagues.
RESEARCH INTERESTS
Dr. Goy’s research interests include new
prognostic markers and development
of medicines in lymphomas. He has a
particular interest in mantle cell lymphoma.
He has served as the lead key investigator
in numerous clinical trials.
DISCLOSURES
Dr. Goy discloses that he is a consultant and
on the speakers’ bureau and advisory board
for Celgene Corporation. Dr. Goy is on the
speakers’ bureau and advisory board for
Takeda Pharmaceutical Company Ltd and
Johnson & Johnson/Pharmacyclics, Inc. He
has received clinical trial support through an
institution from Celgene Corporation and
Johnson & Johnson/Pharmacyclics, Inc.
MANTLE CELL LYMPHOMA HIGHLIGHTS
• Mantle cell lymphoma (MCL) is a relatively rare subtype of non-Hodgkin
lymphoma (NHL)1,2
• The incidence of MCL in the United States is growing and currently
represents approximately 6% to 10% of all new NHL cases annually1-3
• MCL occurs more frequently in patients aged early-mid 60s and more
often in males than in females (incidence ratio of 2.7:1)1,4-7
• The majority of patients are initially diagnosed with advanced disease,
with 74.6% diagnosed with stage III or IV disease6
• Patients with
MCL may present
with extranodal
involvement: blood,
bone marrow, liver,
and gastrointestinal
(GI) tract7-9
• MCL has a poor
long-term prognosis
and is generally
associated with
a high recurrence
rate10
• Patients diagnosed
with MCL typically
have a median
overall survival of
3 to 4 years2
MCL Clinical Presentation1,2,4-11
